Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Exchange Rate Effect (2023 - 2025)

Historic Exchange Rate Effect for Iovance Biotherapeutics (IOVA) over the last 3 years, with Q3 2025 value amounting to -$680000.0.

  • Iovance Biotherapeutics' Exchange Rate Effect fell 15426.98% to -$680000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$611000.0, marking a year-over-year decrease of 11670.31%. This contributed to the annual value of -$541000.0 for FY2024, which is 8025.55% up from last year.
  • Iovance Biotherapeutics' Exchange Rate Effect amounted to -$680000.0 in Q3 2025, which was down 15426.98% from $739000.0 recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Exchange Rate Effect registered a high of $3.0 million during Q4 2023, and its lowest value of -$3.8 million during Q2 2023.
  • Moreover, its 3-year median value for Exchange Rate Effect was -$308000.0 (2024), whereas its average is -$271400.0.
  • Over the last 5 years, Iovance Biotherapeutics' Exchange Rate Effect had its largest YoY gain of 69120.0% in 2025, and its largest YoY loss of 15426.98% in 2025.
  • Iovance Biotherapeutics' Exchange Rate Effect (Quarter) stood at $3.0 million in 2023, then plummeted by 138.99% to -$1.2 million in 2024, then skyrocketed by 42.28% to -$680000.0 in 2025.
  • Its Exchange Rate Effect was -$680000.0 in Q3 2025, compared to $739000.0 in Q2 2025 and $508000.0 in Q1 2025.